(Tiper Stock Exchange) – PharmaNutra, a company specializing in the sector of mineral-based nutritional supplements and medical devices for muscles and joints, announces the acquisition of a new, important strategic asset. There Food Standards Agency (FSA) and Food
Standards Scotland (FSS) – Food Safety Agencies of England, Wales, Northern Ireland and Scotland – have given positive opinion For the classification such as Novel Food by Lipocetthe oral formulation based on cetylated fatty acids (CFA), the same active ingredient used in the products of Cetilar line.
Based on the scientific evidence and information provided by PharmaNutra, the FSA and FSS have concluded that the composition of the new food is safe under the proposed conditions of use and does not present a risk to health. Cetylated Fatty Acids (CFA) are a patented combination of fatty acids of vegetable origin which, in formulations for topical use, have shown to be effective in reducing musculoskeletal pain, so much so that they are a field of research which over the years has already led the company to develop a proprietary patent relating to compositions for topical use, as well as a line of specific medical devices, which today includes the products Cetilar Crema, Cetilar Patch, Cetilar Tape and Cetilar Oro.
“The conclusion of the procedure relating to the approval in Great Britain of Lipocet as a novel food, among other things with a higher dosage
compared to Europe, it is another step towards the global diffusion of our products based on cetylated fatty acids. We are very satisfied with this result because on the one hand it opens us commercially towards a very important country, with excellent prospects, while on the other it is the umpteenth confirmation of the validity of our patent and of the work we have carried out over the years”. comment Germano TarantinoScientific Director of PharmaNutra.
After the positive opinion already obtained in July 2021 from EFSA (European Food Safety Authority) and of the European Commission, which in February 2022 officially authorized the marketing of the new ingredient in the countries of the European Union for which PharmaNutra boasts an exclusive use, now the admissibility therefore also extends to the British territory.